Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.
89bio Q4 EPS $(0.48) Beats $(0.69) Estimate
89bio (NASDAQ:ETNB) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.69) by 30.43 percent. This is a 63.08 percent increase over losses of $(1.30) per share from the same
89bio Data Showed Pegozafermin Treatment Was Found To Be Effective In Reducing Triglycerides And Other Atherogenic Lipids In Patients With SHTG, Regardless Of Their Background Lipid-modifying Therapy
89bio, Inc. (Nasdaq: ETNB) today announced the presentation of additional data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) at the American College of Cardiology's 72nd Annual Scientific Session & Expo Together with World Congress of Cardiology (ACC.23/WCC).
89bio To Present Additional Pegozafermin Data In Severe Hypertriglyceridemia From Phase 2 ENTRIGUE Study At American College Of Cardiology’s Annual Scientific Session Together With World Congress Of Cardiology
89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in pre-market trading.
HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $27 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $27 price target.
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
US Stocks Slightly Lower; Nasdaq Down 100 Points
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 100 points on Monday.
RBC Capital Maintains Outperform on 89bio, Lowers Price Target to $29
RBC Capital analyst Brian Abrahams maintains 89bio (NASDAQ:ETNB) with a Outperform and lowers the price target from $35 to $29.
$9 Million Bet On 89bio? 3 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades.